Related Experiment Video
Updated: May 15, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Toll-like receptor 4 D299G polymorphism in metabolic disorders: a meta-analysis
F S Belforte1, F Coluccio Leskow, E Poskus
1Laboratorio de Biología Molecular: INIGEM CONICET-UBA & Cátedra de Genética y Bilogía Molecular, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Molecular Biology Reports
|January 1, 2013
Summary
The toll-like receptor 4 (TLR4) D299G polymorphism is linked to a reduced risk of metabolic disorders, including type 2 diabetes and metabolic syndrome, particularly in Caucasian populations. This genetic variation may influence innate immune responses involved in these conditions.
Area of Science:
- Immunology
- Genetics
- Metabolic Disorders
Background:
- Toll-like receptor 4 (TLR4) is crucial for innate immunity, recognizing lipopolysaccharides and influencing metabolic disorders like metabolic syndrome (Met-S) and type 2 diabetes mellitus (T2DM).
- Gut microbiota's role in insulin resistance and chronic inflammation is increasingly recognized, potentially interacting with host immune responses.
- Previous studies on the association between TLR4 D299G polymorphism and metabolic disorders have yielded inconsistent results.
Purpose of the Study:
- To systematically review and meta-analyze published data evaluating the association between TLR4 D299G polymorphism and the risk of metabolic disorders.
- To investigate potential differences in this association across different ethnic populations.
Main Methods:
- A systematic review and meta-analysis were conducted on six eligible studies, encompassing 1696 cases and 3388 controls for the TLR4 D299G polymorphism.
- Studies included analyses of type 2 diabetes mellitus (T2DM) and metabolic syndrome (Met-S), with subgroup analyses for Caucasian and mixed populations.
Main Results:
- A significant association was observed between the TLR4 D299G polymorphism and a reduced risk of metabolic disorders (T2DM and Met-S) (OR = 0.566, p = 0.023).
- This protective association was particularly evident in Caucasian populations.
- No significant association was found in the mixed population subgroup, and AG/GG genotypes were linked to decreased metabolic disorder risk.
Conclusions:
- The TLR4 D299G polymorphism, specifically the AG/GG genotypes, is associated with a decreased risk of metabolic disorders, including T2DM and Met-S, especially in Caucasian individuals.
- This finding highlights the potential role of TLR4 genetic variations in modulating susceptibility to metabolic diseases.
- Further research is warranted to elucidate the precise mechanisms underlying this association and population-specific effects.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...